ME03661B - Protutijela protiv amiloidnog beta peptida n3pglu i njihova upotreba - Google Patents

Protutijela protiv amiloidnog beta peptida n3pglu i njihova upotreba

Info

Publication number: ME03661B
Authority: ME; Montenegro
Prior art keywords: amyloid beta; beta peptide; peptide antibodies; n3pglu amyloid; n3pglu
Prior art date: 2010-08-12

Application number

MEP-2019-356A

Other languages

German (de)

English (en)

French (fr)

Inventor

Jirong Lu

Ronald Bradley Demattos

Ying Tang

Original Assignee

Lilly Co Eli

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-08-12

Filing date

2011-08-09

Publication date

2020-07-20

2011-08-09 Application filed by Lilly Co Eli filed Critical Lilly Co Eli

2020-07-20 Publication of ME03661B publication Critical patent/ME03661B/me

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/567—Framework region [FR]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Neurosurgery (AREA)
General Chemical & Material Sciences (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Heart & Thoracic Surgery (AREA)
Psychiatry (AREA)
Cardiology (AREA)
Hospice & Palliative Care (AREA)
Microbiology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

MEP-2019-356A 2010-08-12 2011-08-09 Protutijela protiv amiloidnog beta peptida n3pglu i njihova upotreba ME03661B (me)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US37302610P	2010-08-12	2010-08-12
EP18150424.2A EP3339323B1 (en)	2010-08-12	2011-08-09	Anti-n3pglu amyloid beta peptide antibodies and uses thereof

Publications (1)

Publication Number	Publication Date
ME03661B true ME03661B (me)	2020-07-20

Family

ID=44543826

Family Applications (3)

Application Number	Title	Priority Date	Filing Date
MEP-2019-356A ME03661B (me)	2010-08-12	2011-08-09	Protutijela protiv amiloidnog beta peptida n3pglu i njihova upotreba
MEP-2016-28A ME02352B (me)	2010-08-12	2011-08-09	PROTUTIJELA PROTIV N3pGiu-AMILOlDNOG BETA PEPTlDA l NJIHOVA UPOTREBA
MEP-2018-79A ME03032B (me)	2010-08-12	2011-08-09	Protutijela protiv amiloidnog beta peptida n3pglu i njihova upotreba

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
MEP-2016-28A ME02352B (me)	2010-08-12	2011-08-09	PROTUTIJELA PROTIV N3pGiu-AMILOlDNOG BETA PEPTlDA l NJIHOVA UPOTREBA
MEP-2018-79A ME03032B (me)	2010-08-12	2011-08-09	Protutijela protiv amiloidnog beta peptida n3pglu i njihova upotreba

Country Status (39)

Country	Link
US (2)	US8679498B2 (me)
EP (3)	EP2603523B1 (me)
JP (2)	JP5980207B2 (me)
KR (1)	KR101498833B1 (me)
CN (2)	CN105111308B (me)
AU (1)	AU2011289629B2 (me)
BR (1)	BR112013004056B8 (me)
CA (1)	CA2805114C (me)
CL (1)	CL2013000390A1 (me)
CO (1)	CO6670526A2 (me)
CR (1)	CR20130016A (me)
CY (2)	CY1120144T1 (me)
DK (3)	DK3339323T3 (me)
DO (1)	DOP2013000029A (me)
EA (1)	EA023021B1 (me)
EC (1)	ECSP13012436A (me)
ES (3)	ES2564252T3 (me)
GT (1)	GT201300036A (me)
HK (1)	HK1180703A1 (me)
HR (3)	HRP20160151T1 (me)
HU (2)	HUE028678T2 (me)
IL (2)	IL224030B (me)
LT (2)	LT3042917T (me)
MA (1)	MA34461B1 (me)
ME (3)	ME03661B (me)
MX (2)	MX342782B (me)
MY (2)	MY163521A (me)
NO (1)	NO3042917T3 (me)
NZ (2)	NZ626665A (me)
PE (1)	PE20130817A1 (me)
PH (1)	PH12013500277A1 (me)
PL (3)	PL3042917T3 (me)
PT (2)	PT3339323T (me)
RS (3)	RS59652B1 (me)
SG (2)	SG10201509330XA (me)
SI (3)	SI2603523T1 (me)
UA (1)	UA107600C2 (me)
WO (1)	WO2012021469A1 (me)
ZA (1)	ZA201300437B (me)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL199534A (en)	2007-01-05	2013-01-31	Univ Zuerich	An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
PL3042917T3 (pl) *	2010-08-12	2018-07-31	Eli Lilly And Company	Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie
WO2012136552A1 (en)	2011-04-08	2012-10-11	H. Lundbeck A/S	ANTIBODIES SPECIFIC TO PYROGLUTAMATED Αβ
EP3102611A4 (en) *	2014-02-03	2017-08-23	Cangene Corporation	Humanized beta-amyloid binding molecules and uses thereof
WO2015175769A1 (en)	2014-05-15	2015-11-19	Biogen Ma Inc.	Methods for the detection of amyloid beta oligomers in biological samples
EP3693389B1 (en) *	2014-07-10	2024-09-04	Universität Zürich	Immune-stimulating monoclonal antibodies against human interleukin-2
TWI599358B (zh)	2014-09-16	2017-09-21	美國禮來大藥廠	組合療法
MA41115A (fr)	2014-12-02	2017-10-10	Biogen Int Neuroscience Gmbh	Procédé de traitement de la maladie d'alzheimer
JP2018501482A (ja)	2014-12-19	2018-01-18	プロビオドルグエージー	ｐＧｌｕ−Ａｂｅｔａペプチドの検出のための新規の方法
JO3627B1 (ar)	2015-04-30	2020-08-27	H Lundbeck As	إيميدازو بيرازينونات على هيئة مثبطات pde1
CN106699888B (zh) *	2015-07-28	2020-11-06	上海昀怡健康科技发展有限公司	一种pd-1抗体及其制备方法和应用
ES2901133T3 (es) *	2015-09-23	2022-03-21	Regeneron Pharma	Anticuerpos biespecíficos anti-CD3 optimizados y usos de los mismos
IL260218B2 (en)	2016-01-11	2023-04-01	Novartis Ag	Humanized monoclonal antibodies that elicit an immune response against interleukin-2, and their fusion proteins
JOP20170004B1 (ar) *	2016-01-15	2022-09-15	Lilly Co Eli	الأجسام المضادة لببتيد بيتا النشوي مضاد N3pGlu واستخداماته
AR107783A1 (es) *	2016-03-15	2018-06-06	Lilly Co Eli	Terapia de combinación
AR107774A1 (es) *	2016-03-16	2018-05-30	Lilly Co Eli	Terapia de combinación, método para el tratamiento de la enfermedad de alzheimer
TWI798751B (zh) *	2016-07-01	2023-04-11	美商美國禮來大藥廠	抗－N3pGlu類澱粉β肽抗體及其用途
US10034861B2 (en)	2016-07-04	2018-07-31	H. Lundbeck A/S	1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
US10988529B2 (en)	2016-08-09	2021-04-27	Eli Lilly And Company	Combination therapy
JP2019530647A (ja)	2016-08-18	2019-10-24	イーライリリーアンドカンパニー	Ｂａｃｅ−１阻害剤と抗ｎ３ｐｇｌｕａベータ抗体の併用療法
AR110470A1 (es) *	2016-10-21	2019-04-03	Lilly Co Eli	Terapia de combinación para tratar la enfermedad de alzheimer
MX2019004763A (es)	2016-10-28	2019-07-01	H Lundbeck As	Tratamientos de combinacion que comprenden imidazopirazinonas para el tratamiento de trastornos psiquiatricos y/o cognitivos.
MX2019004859A (es)	2016-10-28	2019-06-20	H Lundbeck As	Tratamientos de combinacion que comprenden la administracion de imidazopirazinonas.
TW201827467A (zh)	2016-11-03	2018-08-01	比利時商健生藥品公司	焦穀胺酸類澱粉蛋白－β之抗體及其用途
JOP20190247A1 (ar) *	2017-04-20	2019-10-20	Lilly Co Eli	أجسام بيتا ببتيد النشوانية المضادة لـ N3pGlu واستخداماتها
CA3070446A1 (en)	2017-07-25	2019-01-31	Immutics, Inc.	Treating cancer by blocking the interaction of tim-3 and its ligand
ES2945165T3 (es)	2017-08-22	2023-06-28	Biogen Ma Inc	Composiciones farmacéuticas que contienen anticuerpos anti-beta-amiloides
AR113926A1 (es)	2017-12-14	2020-07-01	H Lundbeck As	Derivados de 1h-pirazolo[4,3-b]piridinas
PL3723807T3 (pl)	2017-12-14	2022-01-24	H. Lundbeck A/S	Leczenie skojarzone obejmujące podawanie 1h-pirazolo[4,3-b]pirydyn
US11535611B2 (en)	2017-12-20	2022-12-27	H. Lundbeck A/S	Pyrazolo[3,4-B]pyridines and imidazo[1,5-B]pyridazines as PDE1 inhibitors
AU2020245031A1 (en) *	2019-03-26	2021-10-21	Janssen Pharmaceutica Nv	Antibodies to pyroglutamate amyloid-β and uses thereof
MX2022004311A (es)	2019-10-15	2022-05-10	Lilly Co Eli	Estirpes celulares de mamiferos con deficiencia de lipasa/esterasa modificadas geneticamente de manera recombinante.
WO2021257808A2 (en) *	2020-06-17	2021-12-23	Proviva Therapeutics (Hong Kong) Limited	Antibodies to fibroblast activation protein and b7h3
KR20230039734A (ko)	2020-07-23	2023-03-21	오타이르 프로테나 리미티드	항-Aβ 항체
CN116547292A (zh) *	2020-10-02	2023-08-04	伊莱利利公司	用于减少抗体纯化过程中的宿主细胞蛋白质含量的方法和具有减少的宿主细胞蛋白质含量的抗体组合物
TWI843040B (zh)	2021-01-11	2024-05-21	美商美國禮來大藥廠	抗N3pGlu類澱粉β抗體及其用途
TW202300518A (zh)	2021-03-12	2023-01-01	美商美國禮來大藥廠	抗N3pGlu類澱粉β抗體及其用途
TW202300517A (zh)	2021-03-12	2023-01-01	美商美國禮來大藥廠	抗類澱粉β抗體及其用途
AU2022371475A1 (en)	2021-10-22	2024-05-09	Eli Lilly And Company	O-glcnacase (oga) inhibitor combination therapy
CN118475609A (zh)	2021-10-29	2024-08-09	伊莱利利公司	靶向白细胞介素-34的化合物和方法
JP2024542999A (ja)	2021-10-29	2024-11-19	イーライリリーアンドカンパニー	インターロイキン－３４を標的とする化合物及び方法
AU2022376931A1 (en)	2021-10-29	2024-05-02	Eli Lilly Company	Compounds and methods targeting interleukin-34
AR127484A1 (es)	2021-10-29	2024-01-31	Lilly Co Eli	Compuestos y métodos dirigidos a interleucina-34
IL314657A (en)	2022-02-03	2024-09-01	Lilly Co Eli	Regional tau imaging for diagnosing and treating alzheimer's disease
IL318102A (en)	2022-07-21	2025-02-01	Lilly Co Eli	Pharmaceutical solutions of anti-n3pglu aβ antibodies and their uses
TW202440628A (zh)	2022-12-22	2024-10-16	瑞典商生物極公司	新抗體

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8308235D0 (en)	1983-03-25	1983-05-05	Celltech Ltd	Polypeptides
US5225539A (en)	1986-03-27	1993-07-06	Medical Research Council	Recombinant altered antibodies and methods of making altered antibodies
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
US7122374B1 (en) *	2002-04-09	2006-10-17	Takaomi Saido	Amyloid beta-protein 3(pE)-42 antibodies and uses thereof
EP1911765A3 (en)	2002-07-24	2008-04-23	Innogenetics N.V.	Prevention, treatment and diagnosis of diseases associated with Beta-Amyloid formation and/or aggregation
WO2005018424A2 (en) *	2003-08-18	2005-03-03	Research Foundation For Mental Hygiene, Inc.	Antibodies specific for fibrillar amyloid and a procedure to detect fibrillar amyloid deposits
WO2005025616A1 (ja)	2003-09-09	2005-03-24	Takeda Pharmaceutical Company Limited	抗体の用途
JP4851348B2 (ja) *	2004-02-23	2012-01-11	イーライリリーアンドカンパニー	抗Ａβ抗体
KR101068289B1 (ko) *	2004-07-30	2011-09-28	리나트 뉴로사이언스 코퍼레이션	아밀로이드-베타 펩티드에 대해 지시된 항체 및 이의 사용 방법
EP2046833B9 (en)	2006-07-14	2014-02-19	AC Immune S.A.	Humanized antibody against amyloid beta
AU2008242648B2 (en) *	2007-04-18	2013-09-12	Janssen Alzheimer Immunotherapy	Prevention and treatment of cerebral amyloid angiopathy
JP2011522842A (ja)	2008-06-12	2011-08-04	アフィリス・アクチェンゲゼルシャフト	パーキンソン病に関連する症状の治療のための化合物
EP2321348A2 (en)	2008-07-09	2011-05-18	University of Zürich	Method of promoting neurogenesis
KR101706789B1 (ko) *	2008-07-21	2017-02-14	프로비오드룩 아게	진단용 항체 검사법
US8795664B2 (en)	2010-06-04	2014-08-05	Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin	Monoclonal antibodies targeting amyloid beta oligomers
PL3042917T3 (pl) *	2010-08-12	2018-07-31	Eli Lilly And Company	Przeciwciała przeciwko peptydowi beta amyloidu N3pGlu i ich zastosowanie

2011
- 2011-08-09 PL PL15196358T patent/PL3042917T3/pl unknown
- 2011-08-09 ME MEP-2019-356A patent/ME03661B/me unknown
- 2011-08-09 SI SI201130740T patent/SI2603523T1/sl unknown
- 2011-08-09 NZ NZ626665A patent/NZ626665A/en unknown
- 2011-08-09 LT LTEP15196358.4T patent/LT3042917T/lt unknown
- 2011-08-09 DK DK18150424.2T patent/DK3339323T3/da active
- 2011-08-09 CN CN201510613319.6A patent/CN105111308B/zh active Active
- 2011-08-09 ES ES11745672.3T patent/ES2564252T3/es active Active
- 2011-08-09 JP JP2013524156A patent/JP5980207B2/ja active Active
- 2011-08-09 ES ES18150424T patent/ES2764728T3/es active Active
- 2011-08-09 US US13/810,895 patent/US8679498B2/en active Active
- 2011-08-09 ME MEP-2016-28A patent/ME02352B/me unknown
- 2011-08-09 PT PT181504242T patent/PT3339323T/pt unknown
- 2011-08-09 PE PE2013000253A patent/PE20130817A1/es active IP Right Grant
- 2011-08-09 SG SG10201509330XA patent/SG10201509330XA/en unknown
- 2011-08-09 AU AU2011289629A patent/AU2011289629B2/en active Active
- 2011-08-09 DK DK15196358.4T patent/DK3042917T3/en active
- 2011-08-09 EP EP11745672.3A patent/EP2603523B1/en active Active
- 2011-08-09 PL PL18150424T patent/PL3339323T3/pl unknown
- 2011-08-09 MY MYPI2013700226A patent/MY163521A/en unknown
- 2011-08-09 WO PCT/US2011/046994 patent/WO2012021469A1/en active Application Filing
- 2011-08-09 NO NO15196358A patent/NO3042917T3/no unknown
- 2011-08-09 RS RS20191581A patent/RS59652B1/sr unknown
- 2011-08-09 MX MX2013001716A patent/MX342782B/es active IP Right Grant
- 2011-08-09 LT LTEP18150424.2T patent/LT3339323T/lt unknown
- 2011-08-09 KR KR1020137003412A patent/KR101498833B1/ko active Active
- 2011-08-09 EP EP18150424.2A patent/EP3339323B1/en active Active
- 2011-08-09 CN CN201180039876.1A patent/CN103068848B/zh active Active
- 2011-08-09 CA CA2805114A patent/CA2805114C/en active Active
- 2011-08-09 BR BR112013004056A patent/BR112013004056B8/pt active IP Right Grant
- 2011-08-09 PH PH1/2013/500277A patent/PH12013500277A1/en unknown
- 2011-08-09 DK DK11745672.3T patent/DK2603523T3/en active
- 2011-08-09 MY MYPI2016001651A patent/MY181969A/en unknown
- 2011-08-09 HU HUE11745672A patent/HUE028678T2/en unknown
- 2011-08-09 ES ES15196358.4T patent/ES2664128T3/es active Active
- 2011-08-09 EA EA201270813A patent/EA023021B1/ru not_active IP Right Cessation
- 2011-08-09 RS RS20180323A patent/RS57026B1/sr unknown
- 2011-08-09 SI SI201131449T patent/SI3042917T1/en unknown
- 2011-08-09 EP EP15196358.4A patent/EP3042917B1/en active Active
- 2011-08-09 RS RS20160129A patent/RS54685B1/en unknown
- 2011-08-09 PT PT151963584T patent/PT3042917T/pt unknown
- 2011-08-09 ME MEP-2018-79A patent/ME03032B/me unknown
- 2011-08-09 SI SI201131817T patent/SI3339323T1/sl unknown
- 2011-08-09 PL PL11745672T patent/PL2603523T3/pl unknown
- 2011-08-09 MA MA35653A patent/MA34461B1/fr unknown
- 2011-08-09 HU HUE15196358A patent/HUE037524T2/hu unknown
- 2011-08-09 SG SG2013005210A patent/SG187586A1/en unknown
- 2011-08-09 NZ NZ606095A patent/NZ606095A/en unknown
- 2011-09-08 UA UAA201301508A patent/UA107600C2/ru unknown
2012
- 2012-12-31 IL IL224030A patent/IL224030B/en unknown
2013
- 2013-01-16 CR CR20130016A patent/CR20130016A/es unknown
- 2013-01-16 ZA ZA2013/00437A patent/ZA201300437B/en unknown
- 2013-02-05 DO DO2013000029A patent/DOP2013000029A/es unknown
- 2013-02-08 EC ECSP13012436 patent/ECSP13012436A/es unknown
- 2013-02-08 GT GT201300036A patent/GT201300036A/es unknown
- 2013-02-08 CL CL2013000390A patent/CL2013000390A1/es unknown
- 2013-02-12 MX MX2016005533A patent/MX355268B/es unknown
- 2013-02-12 CO CO13028596A patent/CO6670526A2/es unknown
- 2013-07-11 HK HK13108135.4A patent/HK1180703A1/zh unknown
- 2013-09-27 US US14/039,113 patent/US8961972B2/en active Active
2016
- 2016-02-10 HR HRP20160151TT patent/HRP20160151T1/hr unknown
- 2016-04-22 JP JP2016086317A patent/JP6395755B2/ja active Active
2018
- 2018-04-18 HR HRP20180616TT patent/HRP20180616T1/hr unknown
- 2018-04-20 CY CY20181100420T patent/CY1120144T1/el unknown
2019
- 2019-12-12 HR HRP20192233TT patent/HRP20192233T1/hr unknown
2020
- 2020-01-07 CY CY20201100005T patent/CY1122458T1/el unknown
2021
- 2021-07-29 IL IL285226A patent/IL285226B2/en unknown

Also Published As

Publication number	Publication date
CO6670526A2 (es)	2013-05-15
EP3339323A1 (en)	2018-06-27
EA023021B1 (ru)	2016-04-29
CN103068848B (zh)	2015-11-25
HUE028678T2 (en)	2016-12-28
KR20130051989A (ko)	2013-05-21
MY163521A (en)	2017-09-15
ES2764728T3 (es)	2020-06-04
HRP20180616T1 (hr)	2018-07-13
CN105111308A (zh)	2015-12-02
CA2805114C (en)	2017-12-05
DOP2013000029A (es)	2013-03-15
PL2603523T3 (pl)	2016-07-29
IL224030B (en)	2022-04-01
HK1180703A1 (zh)	2013-10-25
DK2603523T3 (en)	2016-03-21
BR112013004056B8 (pt)	2022-10-18
JP6395755B2 (ja)	2018-09-26
PE20130817A1 (es)	2013-07-18
JP5980207B2 (ja)	2016-08-31
ES2664128T3 (es)	2018-04-18
MY181969A (en)	2021-01-15
IL285226B2 (en)	2023-02-01
PT3042917T (pt)	2018-05-02
LT3042917T (lt)	2018-05-10
JP2013536191A (ja)	2013-09-19
CY1122458T1 (el)	2021-01-27
SI3339323T1 (sl)	2019-12-31
JP2016179985A (ja)	2016-10-13
EP3042917A1 (en)	2016-07-13
MA34461B1 (fr)	2013-08-01
DK3339323T3 (da)	2020-01-20
MX342782B (es)	2016-10-12
EP3042917B1 (en)	2018-02-21
HUE037524T2 (hu)	2018-09-28
CN103068848A (zh)	2013-04-24
SG10201509330XA (en)	2015-12-30
RS54685B1 (en)	2016-08-31
NZ626665A (en)	2016-04-29
NZ606095A (en)	2014-11-28
PL3339323T3 (pl)	2020-05-18
CY1120144T1 (el)	2018-12-12
EA201270813A1 (ru)	2013-05-30
NO3042917T3 (me)	2018-07-21
RS59652B1 (sr)	2020-01-31
AU2011289629B2 (en)	2014-07-03
MX355268B (es)	2018-04-11
SI3042917T1 (en)	2018-04-30
EP3339323B1 (en)	2019-11-13
ES2564252T3 (es)	2016-03-21
PT3339323T (pt)	2020-01-14
DK3042917T3 (en)	2018-04-23
ZA201300437B (en)	2014-06-25
ME03032B (me)	2018-10-20
ME02352B (me)	2016-06-20
CL2013000390A1 (es)	2014-03-21
KR101498833B1 (ko)	2015-03-04
SG187586A1 (en)	2013-03-28
HRP20160151T1 (hr)	2016-03-11
WO2012021469A1 (en)	2012-02-16
CA2805114A1 (en)	2012-02-16
HRP20192233T1 (hr)	2020-03-06
SI2603523T1 (sl)	2016-04-29
UA107600C2 (uk)	2015-01-26
PH12013500277A1 (en)	2017-04-21
PL3042917T3 (pl)	2018-07-31
RS57026B1 (sr)	2018-05-31
ECSP13012436A (es)	2013-03-28
LT3339323T (lt)	2020-02-10
EP2603523B1 (en)	2016-01-27
US8679498B2 (en)	2014-03-25
IL285226A (en)	2021-09-30
BR112013004056B1 (pt)	2022-05-17
GT201300036A (es)	2014-07-16
CN105111308B (zh)	2019-03-12
BR112013004056A2 (pt)	2020-08-04
AU2011289629A1 (en)	2013-02-14
US20130142806A1 (en)	2013-06-06
US8961972B2 (en)	2015-02-24
CR20130016A (es)	2013-03-21
EP2603523A1 (en)	2013-06-19
IL285226B (en)	2022-10-01
US20140065138A1 (en)	2014-03-06
MX2013001716A (es)	2013-10-28

Publication	Publication Date	Title
IL285226A (en)	2021-09-30	Antibodies against amyloid beta peptide n3pglu and their uses
IL272831A (en)	2020-04-30	Meditops and antibodies bind meditops and their use
HK1216540A1 (zh)	2016-11-18	抗體及其用途
IL230918A0 (en)	2014-03-31	Modified proteins and peptides
LT2946791T (lt)	2022-01-10	Anti-cd277 antikūnai ir jų panaudojimas
IL222961B (en)	2018-08-30	DNA binding proteins and their uses
PL2721065T3 (pl)	2019-02-28	Przeciwciała anty-angptl3 i ich zastosowanie
HK1179981A1 (zh)	2013-10-11	的抗體及其用途
HK1180601A1 (zh)	2013-10-25	抗體製劑
ZA201206916B (en)	2014-03-26	Oligomer-specific amyloid beta epitope and antibodies
PL2621955T3 (pl)	2018-07-31	Przeciwciała anty-CEACAM6 i ich zastosowania
HK1168622A1 (en)	2013-01-04	Antigen peptide and use thereof
EP2771689A4 (en)	2015-06-03	PEPTIDES USP2A AND ANTIBODIES
GB201121236D0 (en)	2012-01-18	Proteins and peptides
GB201121233D0 (en)	2012-01-18	Modified proteins and peptides
GB201121226D0 (en)	2012-01-18	Modified proteins and peptides